| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue | ¥126.8B | ¥125.0B | +1.5% |
| Operating Income | ¥6.5B | ¥8.1B | -19.6% |
| Profit Before Tax | ¥4.6B | ¥6.7B | -31.2% |
| Net Income | ¥2.8B | ¥4.1B | -31.3% |
| ROE | 2.9% | 4.0% | - |
For the first half of FY2026, Revenue was ¥126.8B (YoY +¥1.8B +1.5%), Operating Income was ¥6.5B (YoY -¥1.6B -19.6%), Ordinary Income was ¥4.8B (YoY -¥2.1B -30.4%), and Net Income was ¥2.8B (YoY -¥1.3B -31.3%), resulting in slight revenue growth but double-digit profit declines. Revenue remained in a flat range, while gross margin improved to 36.6% (prior year 35.4%) up 1.2pt. Selling, general & administrative expenses increased to ¥40.2B (prior year ¥36.9B) up 8.9%, and financial expenses rose to ¥1.9B (prior year ¥1.4B) up 39.0%, compressing the operating margin to 5.1% (prior year 6.5%), down 1.3pt. By segment, the Business Solution segment showed solid performance with Revenue +9.0% and Operating Income +6.0%, while Human Solution recorded Revenue -10.2% and Operating Income -23.6%, worsening profitability and dragging on consolidated results.
[Revenue] Revenue was ¥126.8B (YoY +1.5%), a marginal increase. Segment composition: Business Solution ¥82.9B (65.4% of total, YoY +9.0%), Human Solution ¥43.9B (34.6%, YoY -10.2%). Core Business Solution increased ¥6.8B year-over-year and drove consolidated growth, but Human Solution declined ¥4.9B and offset gains. While reasons for the Human Solution decline were not disclosed, market demand softness and lower utilization are inferred. Trade receivables decreased to ¥33.9B (prior year ¥37.9B), down ¥4.0B, and Days Sales Outstanding (DSO) improved to about 98 days from the prior year, but collection remains long-term. Inventories increased to ¥7.9B (prior year ¥5.0B), up 58.4%, indicating accumulation of project inventory and merchandise.
[Profitability] Gross margin improved to 36.6% (prior year 35.4%), up 1.2pt, reflecting pricing strategy and mix improvements. However, SG&A rose to ¥40.2B (prior year ¥36.9B), up 8.9%, and SG&A ratio increased to 31.7% (prior year 29.6%), up 2.1pt. As a result, Operating Income declined to ¥6.5B (prior year ¥8.1B), down 19.6%, and Operating Margin narrowed to 5.1% (prior year 6.5%), down 1.3pt. Segment operating margins: Business Solution improved to 18.2% (prior year 17.1%), while Human Solution declined to 6.4% (prior year 8.4%), down 2.0pt. Financial expenses increased to ¥1.9B (prior year ¥1.4B), up 39.0%, reflecting higher interest rate environment. Financial income was nearly zero, resulting in non-operating net loss of ¥1.8B. Other income of ¥0.4B less other expenses of ¥0.1B yields Profit Before Tax of ¥4.6B (prior year ¥6.7B), down 31.2%. After corporate taxes of ¥1.8B (effective tax rate 38.6%), Net Income was ¥2.8B (prior year ¥4.1B), down 31.3%, making the pattern of revenue up but profits down clear.
The Business Solution segment (Revenue ¥82.9B, 65.4% share) grew Revenue +9.0% YoY, Operating Income ¥15.1B (YoY +6.0%), and segment margin improved to 18.2% (prior year 17.1%), enhancing profitability. It remains the main driver of consolidated operating income. The Human Solution segment (Revenue ¥43.9B, 34.6% share) declined Revenue -10.2% YoY, Operating Income ¥2.8B (YoY -23.6%), and segment margin fell to 6.4% (prior year 8.4%), down 2.0pt. The combination of revenue decline and margin deterioration in Human Solution pressured consolidated profits. Total segment profit of ¥17.9B, after headquarters and other adjustments, produced consolidated Operating Income of ¥6.5B, indicating a need to improve fixed-cost absorption.
[Profitability] Operating Margin 5.1% (prior year 6.5%), Net Margin 2.2% (prior year 3.3%), shrinking by 1.3pt and 1.1pt respectively. Gross Margin improved to 36.6% (prior year 35.4%) up 1.2pt, but the rise in SG&A ratio to 31.7% (prior year 29.6%) reduced operating profitability. ROE declined to 2.9% (prior year 4.0%). DuPont decomposition: Net Margin 2.2% × Asset Turnover 0.29x × Financial Leverage 4.48x = ROE 2.9%, with Net Margin deterioration as primary driver. [Cash Quality] Operating Cash Flow (OCF) was ¥32.9B (prior year ¥36.8B), down 10.7% YoY, yet 11.7x Net Income of ¥2.8B—high level. Accrual ratio is -6.9% ((Net Income ¥2.8B − OCF ¥32.9B) / Total Assets ¥435.0B), indicating good earnings quality. However, of working capital changes, "Other working capital changes +¥14.1B" materially boosted OCF and may be transitory. [Investment Efficiency] Asset Turnover 0.29x (prior year 0.30x), slightly decreased. Capital expenditure ¥15.1B, intangible investment ¥0.1B. Receivables DSO is about 98 days (Receivables ¥33.9B ÷ (Revenue ¥126.8B / 183 days)), long and indicating room to improve capital efficiency. [Balance Sheet Health] Equity Ratio 22.3% (prior year 24.5%), D/E ratio 3.48x (interest-bearing debt total ¥337.2B / equity ¥97.0B) showing high leverage. Current Ratio about 0.55x (Current Assets ¥70.9B / Current Liabilities approx. ¥128.0B (estimated)) below cautionary level. Interest coverage ~3.4x (EBIT ¥6.5B / Financial Expenses ¥1.9B) in a concerning range. Cash ¥24.6B vs. short-term borrowings ¥52.8B and current lease liabilities ¥16.6B are heavy, making refinancing risk evident.
OCF was ¥32.9B (prior year ¥36.8B, -10.7%), maintaining a high level at 11.7x Net Income ¥2.8B. OCF before working capital changes was ¥38.9B; changes were Inventory increase -¥2.9B, Receivables decrease +¥4.0B, Payables decrease -¥2.5B, Other working capital changes +¥14.1B, followed by corporate tax paid -¥4.1B, interest paid -¥1.9B, lease payments -¥12.8B, resulting in Net cash inflow from operations of ¥32.9B. Other working capital changes +¥14.1B rose substantially from prior year -¥0.3B, likely reflecting increases in accrued expenses and advance receipts, but sustainability requires verification. Investing Cash Flow was -¥16.3B (prior year -¥10.5B), driven by CapEx -¥15.1B, intangible investment -¥0.1B, and lease deposit payments -¥1.3B. Free Cash Flow was ¥16.5B (OCF ¥32.9B − Investing CF ¥16.3B). Financing Cash Flow was -¥27.7B (prior year -¥12.6B): dividend payments -¥7.8B, share buybacks -¥2.7B, lease payments -¥12.8B, debt repayments -¥7.1B, offset by borrowings +¥15.0B, leaving net repayment of approx. ¥7.1B. Consequently, Cash and Cash Equivalents decreased from ¥35.8B at the beginning of the period to ¥24.6B at the end, a decline of -¥11.2B.
Most earnings derive from recurring operating activities; no material one-off gains or losses were recorded. Non-operating income ¥0.4B and non-operating expenses ¥0.1B are both less than 1% of Revenue ¥126.8B and immaterial. Financial expenses ¥1.9B are 1.5% of Revenue and manageable, but financial expense as a percentage of EBIT is high at 29.2%, and the interest burden coefficient is 0.71 (Profit Before Tax ¥4.6B / EBIT ¥6.5B), meaning about 29% of operating profit flows out as interest. Given OCF is 11.7x Net Income and accrual ratio -6.9%, accounting profit and cash generation align and there is no major concern on earnings quality. However, the "Other working capital changes +¥14.1B" that inflated OCF improved from -¥0.3B prior year and may reflect temporary increases in payables or advances; attention to possible reversal in the full year is necessary.
Full year guidance is unchanged: Revenue ¥268.4B (YoY +7.2%), Operating Income ¥27.3B (YoY +13.0%), Net Income ¥16.6B (YoY +14.9%). Progress against H1 results: Revenue 47.2%, Operating Income 23.7%, Net Income 17.0%. Revenue is -2.8pt below the standard 50% progress, Operating Income is -26.3pt, and Net Income is -33.0pt—substantial shortfall at the profit level. The guidance assumes a sharp recovery in H2 to Revenue ¥141.6B (H1 to H2 +11.7%), Operating Income ¥20.8B (H1 to H2 +220.3%), and Net Income ¥13.8B (H1 to H2 +393.5%). This depends on ramp-up of Business Solution projects, decline of H1 front-loaded investment costs, and profitability improvement in Human Solution; given current progress, realization merits close attention. Forecast dividend is ¥10.00 per share (payout ratio approx. 47%), unchanged.
No interim dividend was paid in H1. Full-year dividend forecast is ¥10.00 per share, totaling approx. ¥7.8B. Payout ratio relative to full-year Net Income forecast ¥16.6B is about 47%, a moderate level. In H1, dividend payment of ¥7.8B (year-end prior period dividend) and share buybacks of ¥2.7B were executed, totaling shareholder returns of ¥10.5B. H1 Free Cash Flow ¥16.5B covers dividend and buybacks of ¥10.5B from internal funds; however, total spending including CapEx ¥15.1B is ¥25.6B, still within OCF ¥32.9B, so liquidity is maintained. Treasury shares held are 904k shares (1.1% of issued shares), available for flexible capital policy. Dividend sustainability depends on H2 earnings improvement and OCF levels, and achievement of full-year Net Income forecast is a precondition.
High leverage and liquidity risk: D/E ratio 3.48x, Equity Ratio 22.3% indicate high financial leverage; Current Ratio 0.55x and short-term liabilities approx. 65% of total liabilities indicate thin liquidity buffer. Cash ¥24.6B vs. short-term borrowings ¥52.8B and current lease liabilities ¥16.6B are heavy; refinancing at higher rates or tightened credit conditions present risks. Interest coverage ~3.4x is a concerning level, and interest burden coefficient 0.71 means ~30% of operating profit is consumed by interest; persistent rate increases would pressure profitability and cash flow long-term.
Segment concentration and profitability disparity: Business Solution accounts for 65.4% of Revenue and the majority of operating profit, implying high dependence on a single business. Human Solution recorded Revenue -10.2% and Operating Income -23.6%, with segment margin falling to 6.4% (prior year 8.4%). If demand recovery and utilization improvement in Human Solution lag, consolidated profitability recovery will be constrained and full-year plan probability reduced.
Working capital efficiency and inventory risk: DSO approx. 98 days indicates lengthy collection period, and Inventories rose to ¥7.9B (prior year ¥5.0B) up 58.4%. Inventory accumulation may reflect project progress delays or supply-demand mismatch; if valuation losses or stagnation materialize, profitability and cash flow will suffer. If the OCF boost from "Other working capital changes +¥14.1B" is temporary, a reversal in H2 could impair liquidity.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 5.1% | 14.0% (3.8%–18.5%) | -8.8pt |
| Net Margin | 2.2% | 9.2% (1.1%–14.0%) | -7.0pt |
The company's profitability is well below industry medians, driven mainly by high SG&A ratio and financial expense burden.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 1.5% | 21.0% (15.5%–26.8%) | -19.5pt |
Revenue growth is 19.5pt below the industry median, placing the company in a low-growth position within the sector.
※Source: Company compilation
Execution certainty in H2 to meet full-year plan is the top focus. H1 progress for Operating Income 24% and Net Income 17% shows significant underperformance, while H2 assumes Operating Income +220% and Net Income +394%. Confirming ramp-up of Business Solution projects, profitability improvement in Human Solution, and reduction of H1 front-loaded investments at Q3 is critical.
Financial leverage and liquidity constraints are central to valuation. With D/E 3.48x, Current Ratio 0.55x, and Interest Coverage 3.4x, financial stress is high; prolonged higher rates are a risk. Refinancing conditions for short-term borrowings ¥52.8B and sustainability of OCF (especially whether Other working capital changes +¥14.1B are transient) directly affect liquidity. Improving working capital efficiency (DSO reduction, inventory compression) would support sustained free cash generation to reduce debt and stabilize finances.
Changes in segment mix and profit recovery. Human Solution’s revenue and profit decline weigh on consolidated results, increasing dependence on Business Solution. If demand recovery and utilization in Human Solution are delayed, scope for consolidated margin improvement is limited. Conversely, gross margin improved by +1.2pt; if pricing and mix improvement continue, SG&A absorption and operating leverage could enable margin recovery.
This report is an earnings analysis document automatically generated by AI based on XBRL financial statement data. It does not constitute a recommendation to invest in any particular security. Industry benchmark figures are compiled by the firm from public financial statements and are for reference only. Investment decisions are your responsibility; consult a professional advisor as needed.